Thymopoietin pentapeptide and its synthesis — US4190646A
Patent disclosure · 1980
- What the patent describes
- Solid-phase synthesis of peptides bearing the RKDVY sequence, followed by in vitro lymphocyte differentiation assays.
- Reported evidence
- The original patent reports differentiation of T-cell precursors in a cell assay.
Cell differentiation assay · The grant reports induction of Thy-1-positive T cells in a 1 ng/mL to 10 µg/mL concentration range for the disclosed peptide class. The synthetic peptides did not induce complement-receptor-positive B-cell differentiation.
Reported patent results
Findings described in words
The original patent reports differentiation of T-cell precursors in a cell assay.
Solid-phase synthesis of peptides bearing the RKDVY sequence, followed by in vitro lymphocyte differentiation assays.
Population or model Solid-phase synthesis of peptides bearing the RKDVY sequence, followed by in vitro lymphocyte differentiation assays.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cell differentiation assay | The grant reports induction of Thy-1-positive T cells in a 1 ng/mL to 10 µg/mL concentration range for the disclosed peptide class. The synthetic peptides did not induce complement-receptor-positive B-cell differentiation. |
The reported concentration range describes laboratory activity across the disclosed peptides. The filing provides no patient outcome data.
Source for these results ↗ · Reviewed 2026-11-14
Patent claims and provenance
Molecule. Claims cover the Arg–Lys–Asp–Val–Tyr core, certain terminal substitutions, and compositions and processes using those peptides.
The cell assays describe the same early research program as the 1979 Science paper. They do not establish a separate clinical cohort.
- Publication
- US4190646A ↗ · 1980-02-26
- Earliest priority / filing
- 1975-11-11 / 1979-01-26
- Original applicant / assignee
- Memorial Sloan Kettering Cancer Center
- Indexed status
- Expired - Lifetime · checked 2026-11-14
- Patent family
- 26676220 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Polypeptide compositions and methods
Inventors: Gideon Goldstein; David H. Schlesinger.
Study limitations and source details
Study limitations
- The cell assays describe the same early research program as the 1979 Science paper. They do not establish a separate clinical cohort.
- The reported concentration range describes laboratory activity across the disclosed peptides. The filing provides no patient outcome data.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Related publications may describe some of the same participants or experiments.
Source details
Patent publication · Original patent text and indexed metadata
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Sources checked
Citation
Published
Gideon Goldstein, David H. Schlesinger. Thymopoietin pentapeptide and its synthesis — US4190646A US4190646A · patent family 26676220